Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

The question "what genes affect estrogen levels?" has a longer answer than most women — or their providers — expect. Estrogen biology is not a single-step process governed by one or two genes. It spans at least four distinct biological layers: production (how much estrogen the body makes), metabolism (how estradiol is converted and routed through Phase 1 hydroxylation), clearance (how quickly Phase 2 enzymes inactivate estrogen metabolites for excretion), and receptor response (how sensitively target tissues read the estrogen signal once it arrives). Different genes govern each layer — and genetic variation across all four layers is what explains why two women with the same blood estradiol level can have completely different hormonal experiences. The PlexusDx Precision Peptide Genetic Test analyzes the most functionally significant variants across all four layers as part of 14 pathways, 49 peptides, and 150+ genetic insights.

Layer 1 — Production: Genes That Affect How Much Estrogen Is Made

The primary estrogen production pathway in women runs from cholesterol through a steroid synthesis cascade to estradiol. Two genes at this layer are most relevant to estrogen levels in the context of genetic testing:

CYP19A1 (Aromatase) is the gene encoding aromatase — the enzyme that converts androgens (testosterone, androstenedione) to estrogens (estradiol, estrone). In premenopausal women, aromatase is active in the ovaries and in peripheral tissues including adipose tissue, skin, and bone. In postmenopausal women, peripheral aromatization becomes the dominant source of circulating estrogen. CYP19A1 variants that increase aromatase activity produce more estradiol from the same androgen substrate — directly elevating circulating estrogen levels. Variants that reduce aromatase activity produce less. This is the primary gene governing the quantity of estrogen made, independent of ovarian reserve or hormonal signaling.

SHBG (Sex Hormone Binding Globulin) variants do not affect production directly but govern how much of the estradiol that is produced circulates in bioavailable — receptor-accessible — form. SHBG binds both testosterone and estradiol tightly; high-SHBG variants reduce the free estradiol fraction even when total estradiol is normal. A woman can have a normal total estradiol measurement and significantly reduced free estradiol bioavailability because of SHBG genetics — a distinction that total estrogen tests miss but that shapes the functional estrogen environment at every receptor in her body.

The Precision Peptide Genetic Test's Women's Hormone panel focuses on the metabolism, clearance, and receptor layers rather than CYP19A1 production directly — because the metabolic and clearance genetics are the most clinically modifiable and the least routinely assessed. CYP19A1 context in the Women's Hormone setting is addressed in several of the satellite posts in this series.

Layer 2 — Metabolism: Genes That Shape How Estrogen Is Converted

After production, estradiol enters Phase 1 metabolic processing — hydroxylation by two enzymes whose genetic variants determine the metabolite profile that Phase 2 enzymes must then clear:

CYP1A1 hydroxylates estradiol preferentially at the C-2 position, producing 2-OHE2 — the lower-reactivity, weakly estrogenic catechol estrogen. Higher CYP1A1 activity shifts the Phase 1 output toward the more favorable 2-OHE2 pathway.

CYP1B1 hydroxylates estradiol preferentially at the C-4 position, producing 4-OHE2 — the higher-reactivity catechol estrogen with greater genotoxic potential if not cleared efficiently by COMT. CYP1B1 Leu432Val (rs1056836) is the most studied functional variant, with the Val allele associated with higher enzyme activity and greater 4-OHE2 production. High-activity CYP1B1 variants do not raise circulating estradiol — they change the metabolite ratio that Phase 2 must manage, increasing the downstream reactive burden without changing the starting estradiol measurement.

These Phase 1 variants are covered in depth in CYP1A1 and CYP1B1: Estrogen Metabolism Pathways.

Layer 3 — Clearance: Genes That Determine How Quickly Estrogen Is Eliminated

Phase 2 clearance is where genetic variation has the most direct effect on how long estrogen and its metabolites remain active in circulation — functionally raising or lowering the effective estrogenic exposure at tissues even when the production rate hasn't changed. Four gene variants govern this layer:

COMT Val158Met (rs4680) is the primary rate-limiting enzyme for Phase 2 methylation of catechol estrogens. COMT uses SAMe to methylate 2-OHE2 and 4-OHE2, inactivating them for excretion. Met/Met homozygotes have approximately 60–75% lower COMT activity than Val/Val — meaning catechol estrogens circulate longer before clearance, sustaining a more prolonged estrogenic signal from the same estradiol starting point. COMT does not change the estradiol level on a blood test, but it changes how long the estrogen metabolite picture remains biologically active after each estradiol pulse.

Full detail: COMT Val158Met and Estrogen Clearance.

MTHFR C677T / A1298C affects estrogen clearance indirectly by constraining the methylation cycle that produces SAMe — the methyl donor COMT depends on. T/T MTHFR reduces 5-MTHF production, limits SAMe synthesis, and forces COMT to operate below its Val158Met-determined capacity regardless of COMT genotype. A woman with Val/Val COMT but T/T MTHFR may clear catechol estrogens more slowly than her COMT genotype alone suggests — because the methyl donor supply, not the enzyme structure, is the limiting factor.

Full detail: MTHFR and Methylation: The Women's Hormone Connection.

SULT1A1 Arg213His (rs9282861) governs Phase 2 sulfation — an entirely independent clearance route that inactivates estradiol, estrone, and catechol estrogens through sulfate conjugation without depending on SAMe or the methylation cycle. His/His SULT1A1 reduces this sulfation capacity by approximately 85–90%, leaving more estradiol and its metabolites in bioactive form for longer. Importantly, high SULT1A1 activity builds the estrone sulfate reservoir that peripheral STS activity converts back to free estrone — making SULT1A1 relevant to both clearance speed and the postmenopausal estrogen economy.

Full detail: SULT1A1 Sulfation: Estrogen Detox Genetics.

GSTM1 and GSTT1 null deletions affect the tertiary clearance layer — glutathione conjugation of reactive 4-OHE2-derived quinones. Null GSTM1 and GSTT1 produce zero enzyme activity, eliminating the backstop that prevents reactive estrogen metabolites from reaching DNA when COMT and SULT1A1 are under pressure. While these variants do not directly affect circulating estradiol levels, they shape the downstream consequences of estrogen metabolite accumulation when primary clearance pathways are genetically constrained.

Full detail: GSTM1 and GSTT1: Glutathione and Hormone Detox.

Layer 4 — Receptor Response: Genes That Shape How Tissues Read the Estrogen Signal

The final layer of genetic influence on the estrogen biology picture isn't about estrogen levels at all in the blood-panel sense — it's about how sensitively tissues respond to whatever estrogen does circulate. This distinction is important: two women can have identical estradiol measurements and profoundly different estrogenic experiences at tissue level because their receptor genetics differ.

ESR1 (Estrogen Receptor Alpha) variants — particularly the PvuII-XbaI haplotype (rs2234693 and rs9340799) and the intron 6 poly-A repeat — alter ERα expression efficiency and transcriptional response in bone, breast, uterus, cardiovascular endothelium, and hypothalamus. Higher-sensitivity ESR1 variants amplify the biological effect per unit of circulating estradiol; lower-sensitivity variants attenuate it. ESR1 is the dominant driver of classical estrogenic effects at most hormone-sensitive tissues.

ESR2 (Estrogen Receptor Beta) variants shape ERβ expression and the ERα:ERβ signaling balance — particularly in CNS tissues governing mood, thermoregulation, and cognitive function. ESR2 variants affect not just the magnitude of the estrogen response but the qualitative character of it at different tissue types.

These receptor genetics explain why estrogen blood levels are an incomplete picture of estrogen biology — and why understanding receptor sensitivity genetics alongside production and clearance genetics is essential for interpreting HRT response variability. Full detail: Estrogen Receptor Genetics: ESR1 and ESR2 Variants.

Why "Estrogen Levels" Is the Wrong Frame for Understanding Estrogen Biology

The question "what genes affect estrogen levels?" assumes that estrogen levels — measured in blood — are the primary variable that matters. The genetics reveal a more nuanced picture: what matters is not just the estradiol number but what happens to that estradiol across four sequential biological layers, all of which are genetically variable.

Consider two women with the same total estradiol measurement:

Woman A has high-activity CYP1B1 (generating more reactive 4-OHE2), slow COMT and impaired MTHFR (slowing both Phase 2 methylation clearance pathways), His/His SULT1A1 (eliminating sulfation backup), null GSTM1 (removing glutathione backstop), and high-sensitivity ESR1 (amplifying receptor-level response to whatever catechol estrogens persist). Same estradiol as Woman B. Dramatically higher effective estrogenic exposure at the tissue level because the metabolic and receptor layers compound to extend and amplify the signal.

Woman B has normal CYP1B1 activity (balanced 2-OHE2:4-OHE2 ratio), Val/Val COMT and normal MTHFR (rapid methylation clearance), Arg/Arg SULT1A1 (high sulfation capacity), GSTM1 present (glutathione backstop intact), and lower-sensitivity ESR1 (attenuated receptor response). Same estradiol. Significantly lower functional estrogenic exposure at tissue level — efficient clearance and muted receptor response from the same hormonal starting point.

Neither woman's estradiol measurement differs. Only the genetic context of that measurement differs — and the genetic context is entirely invisible to the blood panel. This is the foundational case for genetic testing of estrogen metabolism pathways: not that blood estrogen panels are wrong, but that they're incomplete without the genetic layer that determines what those numbers actually mean at the cellular level.

What the Precision Peptide Genetic Test Analyzes

The 6 Reproductive Health insights in the Precision Peptide Genetic Test address the metabolism, clearance, and receptor layers of estrogen genetics — the variables that determine what circulating estradiol does, not just how much of it exists. Analysis runs on the Illumina Global Screening Array at CLIA-certified labs, covering 57 unique SNPs across 48 unique genes within a 14-pathway, 150+ insight panel. Results are delivered through the secure PlexusDx Results Portal and provide the genetic context that makes estrogen blood panels clinically interpretable at the individual level.

The complete framework for the Women's Hormone panel — how the six insights work together as a connected system — is in the Complete Guide to Genetic Women's Hormone Testing. How these six variables explain HRT response variability is in Genetics of HRT Response: Why Women React Differently. How they shape the menopause experience specifically is in The Menopause Pathway: What Your Genes Reveal.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to map the genetic variables shaping your estrogen biology? Take the Precision Peptide Genetic Test

Frequently Asked Questions About Genes and Estrogen Levels

What is the most important gene affecting estrogen levels in women?

No single gene dominates — estrogen biology spans four genetic layers: CYP19A1 governs production; CYP1A1/CYP1B1 govern Phase 1 metabolism; COMT, MTHFR, SULT1A1, and GSTM1/GSTT1 govern Phase 2 clearance; ESR1/ESR2 govern receptor response. The Precision Peptide Genetic Test analyzes the clearance and receptor layers as 6 Reproductive Health insights within 14 pathways, 150+ genetic insights.

Can genes cause high estrogen levels in women?

Genetics can increase functional estrogen exposure without raising production. High-activity CYP1B1 generates more reactive 4-OHE2. Slow COMT and impaired MTHFR reduce methylation clearance speed. His/His SULT1A1 near-eliminates sulfation backup. High ESR1 sensitivity amplifies receptor-level response. Each variable extends or amplifies effective estrogen biology independently of the blood estradiol number.

Do estrogen-related genes change over a woman's lifetime?

Genetic variants are fixed at birth and never change. What changes is the context — premenopausal peaks, perimenopausal fluctuation, and postmenopausal estrone dominance interact differently with the same COMT, SULT1A1, and ESR1 genetics. The Precision Peptide Genetic Test maps this fixed genetic baseline across all hormonal life stages within 14 pathways, 150+ insights.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.